Image Source: Zacks Investment Research ... In September, the FDA expanded Dupixent’s label in the CRSwNP indication for use in adolescent patients aged 12 to 17 years. The drug has already ...

The study involved 242 Computed Tomography (CT) images of patients with CRSwNP, constructing a high-quality professional CRSwNP database for the training, validation, and testing of neural networks.

Images from the camera were individually sampled by an acquisition ... Left: Taste intensity testing results (raw mean score) in control, CRSsNP, and CRSwNP patients. Right: Propensity score ...

Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

The following is a summary of “Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps,” published in the January 2025 issue of Annals of Allergy ...

Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

Patients who underwent bilateral treatment experienced a higher rate of clinically relevant recovery, the authors reported.

"Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for patients and health systems." Depemokimab ...

32-provider Springfield Family Physicians harnesses the power of Sunoh.ai and eClinicalWorks Image AI to streamline operations and improve patient care WESTBOROUGH, Mass.--(BUSINESS WIRE ...

This inflammation pathway affects most patients with difficult-to-treat asthma, increasing the risk of exacerbations and hospitalization. It is also found in up to 80% of people with CRSwNP ...